Supernus Pharmaceuticals (SUPN) Free Cash Flow Growth (1y) (2012 - 2026)
Supernus Pharmaceuticals (SUPN) Free Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -109.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -109.26% |
| Mar 31, 2026 | 119.75% |
| Dec 31, 2025 | -56.02% |
| Sep 30, 2025 | -215.89% |
| Jun 30, 2025 | 63.33% |
| Mar 31, 2025 | -20.66% |
| Dec 31, 2024 | -1.78% |
| Sep 30, 2024 | 49.25% |
| Jun 30, 2024 | 286.83% |
| Mar 31, 2024 | -21.89% |
| Dec 31, 2023 | 62.25% |
| Sep 30, 2023 | 158.11% |
| Jun 30, 2023 | -126.77% |
| Mar 31, 2023 | 1,201.57% |
| Dec 31, 2022 | -43.13% |
| Sep 30, 2022 | 436.76% |
| Jun 30, 2022 | 53.62% |
| Mar 31, 2022 | -89.63% |
| Dec 31, 2021 | 53.74% |
| Sep 30, 2021 | -175.59% |